Targeted use of Alpha Particles: Current Status in Cancer TherapeuticsOliver Sartor3,4,5*, Bassam N Maalouf3,4, Carlin R Hauck3 and Roger M Macklis1,2
- *Corresponding Author:
- Oliver Sartor
Laborde Professor of Cancer Research
Tulane Cancer Center
New Orleans, Louisiana, USA
Tel: +504 988 7869
Fax: +504 988 5059
E-mail: [email protected]
Received date: July 12, 2012; Accepted date: August 02, 2012; Published date: August 22, 2012
Citation: Sartor O, Maalouf BN, Hauck CR, Macklis RM (2012) Targeted use of Alpha Particles: Current Status in Cancer Therapeutics. J Nucl Med Radiat Ther 3:136. doi:10.4172/2155-9619.1000136
Copyright: © 2012 Sartor O, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Purpose of review: To summarize the current role of alpha particles in cancer treatment including both clinical and pre-clinical data.
Recent findings: Though discovered more than hundred years ago, no targeted alpha emitters have yet to be approved as a systemic approach to cancer therapy. Until recently, most approaches to target alpha particle emitters utilized conjugation with antibodies through chelators. Limited clinical data are available using this approach; most alpha emitters have been studied in pre-clinical models though 213bismuth has been studied in leukemic patients. The novel alpha emitter 223radium has been studied more extensively than other agents in this class and a recent large randomized phase III trial data with 223radium demonstrates overall survival benefit in castrate resistant prostate cancer patients with skeletal metastasis.
Summary: The alpha emitter 223radium is expected to play a significant future role in therapy for bone-metastatic disease and a variety of novel alpha emitters offer the potential for targeted therapy via conjugation with specific antibodies or targeted nanoparticles.